IL175659A - Pharmaceutical spray formulation comprising a hydrofluoroalkane and an acylated cyclodextrin - Google Patents
Pharmaceutical spray formulation comprising a hydrofluoroalkane and an acylated cyclodextrinInfo
- Publication number
- IL175659A IL175659A IL175659A IL17565906A IL175659A IL 175659 A IL175659 A IL 175659A IL 175659 A IL175659 A IL 175659A IL 17565906 A IL17565906 A IL 17565906A IL 175659 A IL175659 A IL 175659A
- Authority
- IL
- Israel
- Prior art keywords
- formulation according
- alkyl
- hfa
- cyclodextrin
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 12
- 238000009472 formulation Methods 0.000 title claims abstract 11
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 title 1
- 239000007921 spray Substances 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract 4
- 239000000725 suspension Substances 0.000 claims abstract 2
- -1 β-Alanyl Chemical group 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000013583 drug formulation Substances 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims 1
- 125000001980 alanyl group Chemical group 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 1
- 150000004683 dihydrates Chemical class 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- 229960001022 fenoterol Drugs 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 229960001317 isoprenaline Drugs 0.000 claims 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 claims 1
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960002657 orciprenaline Drugs 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000002072 seryl group Chemical group 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
- 229950001669 tipredane Drugs 0.000 claims 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002114 valyl group Chemical group 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0303179A SE0303179D0 (sv) | 2003-11-26 | 2003-11-26 | Novel compounds |
| PCT/GB2004/004957 WO2005053637A2 (en) | 2003-11-26 | 2004-11-24 | Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL175659A0 IL175659A0 (en) | 2006-09-05 |
| IL175659A true IL175659A (en) | 2010-02-17 |
Family
ID=29729189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL175659A IL175659A (en) | 2003-11-26 | 2006-05-15 | Pharmaceutical spray formulation comprising a hydrofluoroalkane and an acylated cyclodextrin |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20070104652A1 (enExample) |
| EP (1) | EP1708679B1 (enExample) |
| JP (1) | JP4950666B2 (enExample) |
| KR (1) | KR20060118509A (enExample) |
| CN (1) | CN100592908C (enExample) |
| AT (1) | ATE413868T1 (enExample) |
| AU (1) | AU2004294775B2 (enExample) |
| BR (1) | BRPI0416992A (enExample) |
| CA (1) | CA2546441C (enExample) |
| CY (1) | CY1108753T1 (enExample) |
| DE (1) | DE602004017783D1 (enExample) |
| DK (1) | DK1708679T3 (enExample) |
| ES (1) | ES2314469T3 (enExample) |
| IL (1) | IL175659A (enExample) |
| MX (1) | MXPA06005643A (enExample) |
| NO (1) | NO20062969L (enExample) |
| NZ (1) | NZ547355A (enExample) |
| PL (1) | PL1708679T3 (enExample) |
| PT (1) | PT1708679E (enExample) |
| SE (1) | SE0303179D0 (enExample) |
| SI (1) | SI1708679T1 (enExample) |
| WO (1) | WO2005053637A2 (enExample) |
| ZA (1) | ZA200604330B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006008568A (ja) * | 2004-06-24 | 2006-01-12 | Cyclochem:Kk | ＩｇＥ抗体抑制剤および食品 |
| JPWO2023127219A1 (enExample) * | 2021-12-28 | 2023-07-06 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| US5654442A (en) * | 1989-11-14 | 1997-08-05 | The Perkin-Elmer Corporation | 4,7-dichlorofluorescein dyes as molecular probes |
| TW249226B (enExample) * | 1990-04-04 | 1995-06-11 | Aderk Ueno Kk | |
| EP0477931B1 (en) * | 1990-09-28 | 1994-08-17 | Mercian Corporation | Novel adriamycin derivatives |
| FR2692168B1 (fr) * | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| US5916883A (en) * | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| GB2326334A (en) * | 1997-06-13 | 1998-12-23 | Chiesi Farma Spa | Pharmaceutical aerosol compositions |
| GB9807232D0 (en) * | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| DE10205087A1 (de) * | 2002-02-07 | 2003-08-21 | Pharmatech Gmbh | Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln |
-
2003
- 2003-11-26 SE SE0303179A patent/SE0303179D0/xx unknown
-
2004
- 2004-11-24 DK DK04798662T patent/DK1708679T3/da active
- 2004-11-24 NZ NZ547355A patent/NZ547355A/en not_active IP Right Cessation
- 2004-11-24 PT PT04798662T patent/PT1708679E/pt unknown
- 2004-11-24 BR BRPI0416992-1A patent/BRPI0416992A/pt not_active IP Right Cessation
- 2004-11-24 AU AU2004294775A patent/AU2004294775B2/en not_active Ceased
- 2004-11-24 ES ES04798662T patent/ES2314469T3/es not_active Expired - Lifetime
- 2004-11-24 PL PL04798662T patent/PL1708679T3/pl unknown
- 2004-11-24 JP JP2006540609A patent/JP4950666B2/ja not_active Expired - Fee Related
- 2004-11-24 CN CN200480040939A patent/CN100592908C/zh not_active Expired - Fee Related
- 2004-11-24 KR KR1020067010242A patent/KR20060118509A/ko not_active Ceased
- 2004-11-24 SI SI200430972T patent/SI1708679T1/sl unknown
- 2004-11-24 WO PCT/GB2004/004957 patent/WO2005053637A2/en not_active Ceased
- 2004-11-24 AT AT04798662T patent/ATE413868T1/de active
- 2004-11-24 DE DE602004017783T patent/DE602004017783D1/de not_active Expired - Lifetime
- 2004-11-24 CA CA2546441A patent/CA2546441C/en not_active Expired - Fee Related
- 2004-11-24 MX MXPA06005643A patent/MXPA06005643A/es active IP Right Grant
- 2004-11-24 EP EP04798662A patent/EP1708679B1/en not_active Expired - Lifetime
- 2004-11-24 US US10/580,589 patent/US20070104652A1/en not_active Abandoned
-
2006
- 2006-05-15 IL IL175659A patent/IL175659A/en not_active IP Right Cessation
- 2006-05-25 ZA ZA200604330A patent/ZA200604330B/en unknown
- 2006-06-26 NO NO20062969A patent/NO20062969L/no not_active Application Discontinuation
-
2009
- 2009-01-19 CY CY20091100063T patent/CY1108753T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004294775B2 (en) | 2007-12-20 |
| ZA200604330B (en) | 2007-11-28 |
| HK1108390A1 (zh) | 2008-05-09 |
| US20070104652A1 (en) | 2007-05-10 |
| JP2007515401A (ja) | 2007-06-14 |
| PT1708679E (pt) | 2008-12-29 |
| NO20062969L (no) | 2006-08-25 |
| CY1108753T1 (el) | 2014-04-09 |
| JP4950666B2 (ja) | 2012-06-13 |
| SE0303179D0 (sv) | 2003-11-26 |
| WO2005053637A3 (en) | 2007-06-28 |
| CN101087600A (zh) | 2007-12-12 |
| CA2546441C (en) | 2011-11-22 |
| DE602004017783D1 (de) | 2008-12-24 |
| CA2546441A1 (en) | 2005-06-16 |
| KR20060118509A (ko) | 2006-11-23 |
| ES2314469T3 (es) | 2009-03-16 |
| ATE413868T1 (de) | 2008-11-15 |
| WO2005053637A2 (en) | 2005-06-16 |
| EP1708679B1 (en) | 2008-11-12 |
| CN100592908C (zh) | 2010-03-03 |
| IL175659A0 (en) | 2006-09-05 |
| SI1708679T1 (sl) | 2009-04-30 |
| BRPI0416992A (pt) | 2007-02-06 |
| PL1708679T3 (pl) | 2009-04-30 |
| NZ547355A (en) | 2009-05-31 |
| EP1708679A2 (en) | 2006-10-11 |
| AU2004294775A1 (en) | 2005-06-16 |
| MXPA06005643A (es) | 2006-08-17 |
| DK1708679T3 (da) | 2009-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2745064T3 (es) | Formulación superfina de formoterol | |
| US6120752A (en) | Medicinal aerosol products containing formulations of ciclesonide and related steroids | |
| CA2421976A1 (en) | Medicaments | |
| RU98118908A (ru) | Баллон для доставки фармацевтического состава, дозирующий ингалятор | |
| ATE216575T1 (de) | Treibgasmischung für eine aerosolzubereitung | |
| US6264923B1 (en) | Medicinal aerosol formulation of ciclesonide and related compounds | |
| US12370141B2 (en) | Pharmaceutical aerosol product for administration by oral or nasal inhalation | |
| IL175659A (en) | Pharmaceutical spray formulation comprising a hydrofluoroalkane and an acylated cyclodextrin | |
| US20130125882A1 (en) | Method and composition for treating asthma and copd | |
| ES2259915B1 (es) | Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion. | |
| EP1359902B1 (en) | Bimodal dry powder formulation for inhalation | |
| JP2007515401A5 (enExample) | ||
| AU702880B2 (en) | Aerosol drug formulations | |
| CN1728984A (zh) | 以卵磷脂为表面活性剂的可控制剂量的气雾剂 | |
| TH29544B (th) | สูตรผสมรูปแบบละอองลอยทางเภสัชกรรมซึ่งมีสารรักษาโรคและตัวผลักดันชนิดไฮโดรฟลูโอโรคาร์บอน | |
| MXPA99010646A (es) | Productos medicinales en aerosol | |
| HK1108390B (en) | Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin | |
| AU2002231939A1 (en) | Bimodal dry powder formulation for inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |